PCRX - Pacira BioSciences, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

PCRX

PACIRA BIOSCIENCES, INC.

NASDAQ

$25.05

▼ DOWN 0.63% (-0.16)

KEY STATISTICS

Market Cap$985.34 M

52w High$27.66

52w Low$18.80

Dividend Yield—

Frequency—

P/E9.63

Volume560.21K

Shares Out.39.34M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Frank D. Lee

COMPENSATION 2026

Salary$634,038

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$91,152

Total$727,378

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 3, 2011

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

827

PRICE TARGET

Target High$32.00

Target Low$25.00

Target Median$30.00

Target Consensus$29.40

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$183.04M

NOV

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

213

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

80.64%

HOLDERS

412

TOP 8 OF 412 · RANKED BY POSITION SIZE

Doma Perpetual Capital Management LLC

2.8M sh

$70.47M

Dimensional Fund Advisors LP

2.2M sh

$55.75M

Renaissance Technologies LLC

D. E. Shaw & Co., Inc.

2.0M sh

$52.79M

PRICE

$25.05 ▼ DOWN 0.63% (−$0.16)

About Pacira BioSciences, Inc.

https://www.pacira.com ↗

Pacira BioSciences, Inc. develops non-opioid pain management and regenerative health solutions, including EXPAREL, ZILRETTA, and iovera, utilizing innovative drug delivery technologies for healthcare providers in the U.S.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT PACIRA BIOSCIENCES, INC. IS KNOWN FOR

EXPAREL

EXPAREL is a long-acting, non-opioid local anesthetic used during surgery to provide postsurgical pain relief and reduce opioid dependence, serving as Pacira's flagship product and key revenue driver.

COMPETITORS

COMPETITOR

BHC COMPARE

COLL COMPARE

HRTX COMPARE

Pacira BioSciences in 2025

SENTIMENT: − NEGATIVE

EARNINGS · JANUARY 2026 (FOR FULL-YEAR 2025 RESULTS)

Pacira BioSciences Stock Plunges After Preliminary 2025 Revenue Misses Expectations, Signaling Growth Concerns

In early January 2026, Pacira BioSciences announced preliminary full-year 2025 revenue of $726.4 million, which fell short of analyst consensus estimates. The announcement also highlighted slowing sales growth and pricing pressures, which triggered a significant negative reaction from investors concerned about the company's future growth trajectory.

RESTRUCTURING · JULY 2025 · IN PROGRESS

Pacira Lays Off 8% of Workforce and Decommissions Facility to Boost EXPAREL Manufacturing Efficiency and Margins

Pacira initiated a significant operational restructuring by laying off 71 employees and decommissioning an older manufacturing facility in San Diego. This move is intended to streamline the production of its flagship product, EXPAREL, by consolidating operations into newer, larger-scale sites, directly supporting the company's goal of improving gross margins.

Latest News

GLOBENEWSWIRE · OCT 5, 2026

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sparing postsurgical pain management across European markets.

READ ARTICLE

EARLIER COVERAGE

DEFENSE WORLD · SEP 28, 2026

240,006 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Bank of America Corp DE

Bank of America Corp DE bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 240,006 shares of the company's stock, valued at approximately $6,089,000. Bank of America

READ ARTICLE